NZ Lymphoma / Leukaemia Research Review Issue 42

In this issue:

Leukaemia selection
Venetoclax-rituximab in relapsed or refractory CLL
Prognostic indicators in primary plasma-cell leukaemia
Second-line dasatinib discontinuation in CML
Ph– cytogenetic abnormalities in CML
Residual disease at induction redefines PR in AML

Lymphoma selection
Ibrutinib-venetoclax for mantle-cell lymphoma
Ibrutinib-rituximab in Waldenström’s macroglobulinaemia
CHOP vs. GEM-P in previously untreated peripheral T-cell lymphoma
DLBCL: genetics and pathogenesis
Brentuximab vedotin-nivolumab in relapsed/refractory
Hodgkin’s lymphoma

Please login below to download this issue (PDF)